scholarly journals Paraneoplastic Opsoclonus Myoclonus in a Patient with Pancreatic Adenocarcinoma

2019 ◽  
Vol 2019 ◽  
pp. 1-3
Author(s):  
Divine C. Nwafor ◽  
Ashley B. Petrone ◽  
Joseph M. Collins ◽  
Amelia K. Adcock
Keyword(s):  
Saccadic Eye Movements ◽  
Small Cell ◽  
Ductal Adenocarcinoma ◽  
Small Cell Lung ◽  
The Third ◽  
Pancreatic Malignancy ◽  
Underlying Malignancy ◽  
Published Report ◽  
Opsoclonus Myoclonus Syndrome ◽  
Adenocarcinoma Of The Pancreas

Opsoclonus myoclonus syndrome (OMS) is an extremely rare neurological syndrome typically affecting as few as 1 in 10,000,000 people annually. OMS is characterized by the presence of involuntary, saccadic eye movements, as well as ataxia, including gait incoordination, rigidity, and tremor. The origin of OMS is unclear, but a significant percentage of OMS cases are indicative of an underlying malignancy, most commonly neuroblastoma and small cell lung cancer. Here we describe an adult patient with OMS, who was ultimately diagnosed with a small ductal adenocarcinoma of the pancreas. To our knowledge, this is the third published report of an association between OMS and pancreatic malignancy, and the only case where the pancreatic malignancy was detected prior to metastasis or autopsy at death. This case report highlights the importance of careful, aggressive malignancy screening with OMS, as the pancreatic duct cut-off sign may be overlooked if pancreatic malignancy is not suspected.

scholarly journals Combination of bevacizumab and dual immunotherapy for extensive-disease small-cell lung cancer: a case report

Immunotherapy ◽  
2021 ◽  
Author(s):  
Lei Song ◽  
Rengui Zhou ◽  
Xiangyong Li ◽  
Dejian Pan
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Survival Time ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Line Treatment ◽  
Small Cell Lung ◽  
Extensive Disease ◽  
The Third ◽  
Third Line

Small-cell lung cancer (SCLC) is sensitive to chemoradiotherapy but remains to have a poor prognosis. In the immunotherapy era, chemotherapy combined with PD-L1 inhibitors has become a new first-line treatment option for advanced SCLC. The CheckMate 032 study combined a PD-1 blockade and a CTLA-4 inhibitor and found that this dual immunotherapy might be a positive treatment choice for SCLC. In our case, the patient with advanced SCLC received bevacizumab combined with dual immunotherapy over the third line with more than 12 months survival time. The overall survival time was 21.5 months from the start of the third-line treatment and 39 months from the time of extensive-disease SCLC diagnosis. The combination of a VEGF blockade and a dual immunotherapy in SCLC resulted in synergistic treatment effects. Therefore, bevacizumab might be a better adjuvant, either combined with chemotherapy or dual immunotherapy, for patients with persistent disease progression after undergoing immunotherapy.

Phase III trial of concurrent thoracic radiotherapy (TRT) with either the first cycle or the third cycle of cisplatin and etoposide chemotherapy to determine the optimal timing of TRT for limited-disease small cell lung cancer.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 7004-7004 ◽  
Author(s):  
Keunchil Park ◽  
Jong-Mu Sun ◽  
Sang-We Kim ◽  
Myung-ju Ahn ◽  
Jin Seok Ahn ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Febrile Neutropenia ◽  
Complete Response ◽  
Small Cell ◽  
Thoracic Radiotherapy ◽  
Small Cell Lung ◽  
Limited Disease ◽  
Once Daily ◽  
The Third ◽  
To Receive

7004 Background: Concurrent thoracic radiotherapy (TRT) with chemotherapy has been regarded as optimal treatment for limited-disease small cell lung cancer (SCLC). However, the issue on how early TRT should be commenced is not yet defined. Methods: A total of 219 patients with limited-disease SCLC, who were enrolled from July 2003 to June 2010, received four cycles of cisplatin plus etoposide (cisplatin 70 mg/m2 on day 1 and etoposide 100 mg/m2 on days 1 to 3 every 3 weeks). We randomly assigned these patients to receive concurrent TRT, beginning with the first cycle (initial arm) or the third cycle (delayed arm) of chemotherapy. In both arms, patients received 2.1 Gy once-daily in 25 fractions over a period of five weeks, with a total dose of 52.5 Gy. Patients with partial or complete response were recommended to receive prophylactic cranial irradiation (PCI). Results: Approximately 82% of patients completed planned four cycles of chemotherapy with 52.5 Gy TRT (81.1% and 82.4% in the initial and delayed arm, respectively). After a median follow-up of 4.9 years (range, 1.2 – 8.1 years), the median overall survivals were 24.1 and 26.8 months (P=0.60) in the initial and delayed arm, respectively. Progression-free survival and complete response rates were 12.2 vs. 12.1 months (P=0.94) and 36.0% vs. 38.0% (P=0.77) in the initial and delayed arms, respectively. PCI was given to 49.5% and 55.6% of patients in the initial and delayed arms, respectively (P = 0.37). Febrile neutropenia was significantly more frequent with the initial arm, occurring in 21.6% of patients, as compared with 10.2% in the delayed arm (P = 0.02). All grade esophagitis occurred in 45.0% and 37.0% of the initial and delayed arms, respectively (p = 0.23). Conclusions: TRT (52.5 Gy, once daily) beginning with the third cycle of chemotherapy showed comparable survival outcomes and complete response rates with TRT beginning with the first cycle of chemotherapy, with a lower frequency of febrile neutropenia.

scholarly journals Patterns of Care for Non–Small-Cell Lung Cancer at an Academic Institution Affiliated With a National Cancer Institute–Designated Cancer Center

2012 ◽  
Vol 8 (1) ◽  
pp. 57-62 ◽  
Author(s):  
Kim-Son H. Nguyen ◽  
Rachel A. Sanford ◽  
Mark S. Huberman ◽  
Michael A. Goldstein ◽  
Danielle M. McDonald ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Stage Iv ◽  
Small Cell ◽  
Cancer Center ◽  
Evidence Based ◽  
Small Cell Lung ◽  
The Third ◽  
Use Of Resources ◽  
Third Line ◽  
Line Setting

These data point toward the need for improved evidence-based use of resources in the third-line setting of stage IV NSCLC.

scholarly journals Opsoclonus-myoclonus syndrome and exaggerated startle response associated with small-cell lung cancer

2011 ◽  
Vol 26 (9) ◽  
pp. 1768-1769 ◽  
Author(s):  
Elias S. Sotirchos ◽  
E. Ray Dorsey ◽  
Ik Lin Tan ◽  
David S. Zee
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Startle Response ◽  
Small Cell ◽  
Small Cell Lung ◽  
Opsoclonus Myoclonus Syndrome

EPID-02. COUNTY MEDIAN FAMILY INCOME AS PROGNOSTIC FACTOR IN NON-SMALL-CELL LUNG CANCER WITH BRAIN METASTASES AT PRESENTATION: A POPULATION-BASED STUDY

2021 ◽  
Vol 23 (Supplement_6) ◽  
pp. vi86-vi86
Author(s):  
Ignacio Jusue-Torres ◽  
Alicia Hulbert ◽  
Jehad Zakaria ◽  
Kathy S Albain ◽  
Courtney Hentz ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Brain Metastasis ◽  
Household Income ◽  
Population Based ◽  
Small Cell ◽  
Proportional Hazard ◽  
Small Cell Lung ◽  
Population Based Study ◽  
The Third ◽  
Cox Proportional Hazard

Abstract INTRODUCTION The purpose of this study was to characterize the impact of household income disparities in the survival of patients with non-small cell lung cancer (NSCLC) presenting with brain metastasis on a population-based level. METHODS This is a population-based cohort study using the SEER database from 2010-2016 including 15,808 NSCLC patients presenting with brain metastasis. Two-tailed log-rank test was used to compare overall survival between groups and association with survival was quantified using hazard ratios (HR) with 95 % confidence intervals (CI) assessed with univariate and multivariate Cox proportional hazard models. RESULTS Patients living in low-income counties had a median survival of 4 months when compared to 5 months for patients living in high-income counties respectively (p< 0.0001). Patients living in first and second bottom quartiles had a median survival of 4 months and 5 months and 6 months for the third and fourth top quartiles, respectively (p< 0.0001). The 1-, 2- and 5-year survival rates for living in the lower household income quartile were 21, 10 and 3% respectively, for the second quartile 24, 10 and 3%; for the third quartile 28, 14 and 4% and for the top fourth quartile 31, 17 and 4% respectively. Multivariate cox proportional hazard analysis adjusted for age, gender, race, hispanic ethnicity, marital status, insurance status, percentage of high school education in the patient’s county, histology, presence of lung metastasis, bone metastasis, liver metastasis, radiation received, surgery performed, and chemotherapy received showed that living in higher quartile household income county is associated with decrease mortality risk (p < 0.0001) HR 0.87 95% CI (0.82-92). CONCLUSION This population-based study suggests that living in higher median household income counties is associated with increased survival time and reduced risk of mortality for patients with NSCLC who have brain metastases present at diagnosis, independent of other factors.

Phase I and pharmacokinetic study of bexarotene in combination with gefitinib in the third-line treatment of non-small-cell lung cancer

2013 ◽  
Vol 24 (7) ◽  
pp. 731-735 ◽  
Author(s):  
Sukhmani K. Padda ◽  
Laveena Chhatwani ◽  
Lisa Zhou ◽  
Charlotte D. Jacobs ◽  
Arturo Lopez-Anaya ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Phase I ◽  
Small Cell Lung Cancer ◽  
Pharmacokinetic Study ◽  
Small Cell ◽  
Line Treatment ◽  
Small Cell Lung ◽  
The Third ◽  
Third Line ◽  
Third Line Treatment
Sign in / Sign up

Export Citation Format

Share Document